argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
|Articles|April 1, 2020
- BioPharm International-04-01-2020
- Volume 33
- Issue 4
Chromatography Columns
Shim-pack Bio Diol and IEX columns from Shimadzu Scientific Instruments improve the accuracy of the characterization of peptides, oligonucleotides, and other biopharmaceuticals.
Advertisement
Shim-pack Bio Diol and IEX columns from Shimadzu Scientific Instruments improve the accuracy of the characterization of peptides, oligonucleotides, and other biopharmaceuticals. The columns are available in quaternary ammonium and sulfopropyl chemistries and are positioned on porous and non-porous hydrophilic polymers with low nonspecific adsorption.
The columns come equipped with different pore sizes for an accurate analysis of aggregates and fragments of monoclonal antibodies, oligonucleotides, and carbohydrates. Particle sizes from 5 μm to 2 μm can be reduced, which improves the resolution between aggregates and monomers. The column lengths can also be reduced from 300 mm to 150 mm using a 2 μm particle, which leads to a 50% shorter run time while keeping up with resolution.
Articles in this issue
over 6 years ago
Bioreactors Redefine Upstream Productivityover 6 years ago
Critical Knowledge for Preparing Auditsover 6 years ago
Can Vaccine Development Be Safely Accelerated?over 6 years ago
What’s New in Downstream Technologiesover 6 years ago
Benchtop Centrifugesover 6 years ago
Ensuring Smooth Tech Transfer of Bioprocess Operationsover 6 years ago
Biosimilars Tackle Interchangeability Standardsover 6 years ago
Contamination Control for Cell Therapyover 6 years ago
Packaging Preserves the Cold ChainAdvertisement
Related to this article
A single subcutaneous dose of Janux’s CD19-targeted T-cell engager JANX011 depleted more than 90% of B cells in three of five healthy volunteers at the top dose, with only Grade 1 cytokine release syndrome. Patient studies in immune thrombocytopenia and rheumatoid arthritis are planned for 2027.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
In a phase 1 study, Johnson & Johnson’s combination of pasritamig and JNJ-9401, two bispecific antibodies targeting KLK2 and PSMA, cut PSA by at least 50% in 73% of patients with metastatic castration-resistant prostate cancer. The regimen is now in phase 3.
A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
Advertisement
Advertisement
Trending on BioPharm International
1
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
2
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
3
Alethio Raises $90 Million to Advance First-in-Class G6B Antibody for Essential Thrombocythemia
4
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
5